中国药师2017,Vol.20Issue(1) :106-108.

羧甲司坦联合布地奈德治疗哮喘的疗效及对血清炎症因子的影响

Clinical Efficacy and Effects on Serum Inflammatory Factors of Carbocisteine Combined with Budesonide in the Treatment of Asthma

张惠燕
中国药师2017,Vol.20Issue(1) :106-108.

羧甲司坦联合布地奈德治疗哮喘的疗效及对血清炎症因子的影响

Clinical Efficacy and Effects on Serum Inflammatory Factors of Carbocisteine Combined with Budesonide in the Treatment of Asthma

张惠燕1
扫码查看

作者信息

  • 1. 东阳市人民医院巍山分院内科 浙江金华322109
  • 折叠

摘要

目的::探讨羧甲司坦联合布地奈德治疗哮喘的临床疗效及对血清炎症因子的影响。方法:186例哮喘患者随机分为观察组(93例)和对照组(93例),对照组于常规治疗基础上给予布地奈德治疗,观察组患者于对照组治疗基础上给予羧甲司坦治疗,1周为一个疗程。观察两组患者疗效。应用初期呼吸阻力( Rrsc)和莱斯特咳嗽问卷( LCQ)分别评估气道反应性及患者咳嗽状况,观察患者日、夜间症状改善;检测血清炎症因子水平,并评估其安全性。结果:治疗后两组LCQ 评分较前明显升高, Rrsc、日、夜间症状评分,及血清白细胞介素-8(IL-8)、肿瘤坏死因子-α(TNF-α)和IgE水平则均较前显著下降(P<0.05);且治疗后观察组各项指标均明显优于对照组(P<0.05)。观察组显效率为86.02%,高于对照组的77.42%,但差异无统计学意义(P>0.05);两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:羧甲司坦联合布地奈德治疗哮喘能够显著改善患者哮喘症状,咳嗽减轻,炎症因子降低,且具有较高的安全性。

Abstract

Objective:To explore the clinical efficacy and the effects on serum inflammatory factors of carbocisteine and budes-onide in the treatment of asthma. Methods:Totally 186 asthma patients were randomly divided into the observation group (93 cases) and the control group (93 cases). The control group received budesonide combined with the conventional treatment, the observation group was treated with carbocisteine and budesonide, and one week was a treatment course. The efficacy was observed. The airway re-sponsiveness and cough condition was respectively assessed by early respiratory resistance ( Rrsc) and Leicester cough questionnaire ( LCQ) . The improvement of day and night symptoms was observed, and the serum levels of inflammatory factors and the safety were also evaluated. Results:LCQ score of the observation group after the treatment was significantly higher than that of the control group, Rrsc score for day and night symptoms and serum IL-8, TNF-αand IgE levels were significantly lower than those in the control group, and the differences were statistically significant (P<0. 05). The effective rate of the observation group was 86. 02%, which was high-er than that of the control group (77. 42%), while the difference was not statistically significant (P>0. 05). The difference in the in-cidence of ADR between the groups was not statistically significant (P>0. 05). Conclusion: Carbocisteine and budesonide in the treatment of asthma can significantly improve asthma symptoms and reduce cough and inflammatory cytokines with promising safety.

关键词

羧甲司坦/布地奈德/哮喘/疗效/血清炎症因子

Key words

Carbocisteine/Budesonide/Asthma/Efficacy/Serum inflammatory factors

引用本文复制引用

出版年

2017
中国药师
国家药品监督管理局高级研修学院,武汉医药(集团)股份有限公司

中国药师

CSTPCD
影响因子:0.944
ISSN:1008-049X
被引量23
参考文献量11
段落导航相关论文